AstraZeneca PLC
AZN68.460USD
Today
-7.38%
5 Days
-7.21%
1 Month
-11.63%
6 Months
-11.63%
Year to Date
+4.48%
1 Year
+1.49%
Agency Rating
Analyst Rating
Peer Comparison
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
News
AstraZeneca breast cancer drug shows positive results, shares up
Investing.com -- AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the illness during a late-stage clinical trial.

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
Feb 20 (Reuters) - AstraZeneca AZN.L will buy longtime partner FibroGen's FGEN.O China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.
